骨质疏松症肠外疗法的持续性与依从性:一项系统综述
该系统综述检索PubMed、Medline和EMBASE截至2018年9月的文献,纳入40项观察性研究,评估成人骨质疏松症患者对特立帕肽皮下注射、伊班膦酸静脉注射、唑来膦酸静脉注射和地舒单抗皮下注射的依从性与持续性。结果显示减少给药频率的肠外药物依从性高于口服疗法,但各项研究报告的持续性和依从率存在显著异质性,多数数据来自短期研究,需要评估长期依从性与持续性。
要点
- 特立帕肽1年持续性10-87%(中位数55%),2年10-69%(中位数29.5%)。
- 唑来膦酸第二剂持续性34-73%(中位数42%),第三剂20-54%(中位数35.8%)。
- 地舒单抗第二剂(1年)持续性61-100%(中位数81%),第四剂(2年)36-99%(中位数45.5%)。
核心结论
- 减少给药频率的肠外骨质疏松药物依从性高于口服疗法。
- 各研究报告的持续性和依从率存在显著异质性,多数已发表数据来自短期研究,需要评估肠外骨质疏松疗法的长期依从性与持续性。
研究设计与样本
- 系统综述检索PubMed、Medline和EMBASE数据库中截至2018年9月发表的英文观察性研究。
- 纳入评估成人骨质疏松症患者对特立帕肽皮下注射、伊班膦酸静脉注射、唑来膦酸静脉注射和地舒单抗皮下注射依从性和/或持续性的研究。
- 排除仅有自我报告的依从性或持续性数据的研究以及患者少于20例的研究。
- 使用纽卡斯尔-渥太华质量评估量表(NOS)对纳入研究进行质量评估。
- 共纳入40项符合条件的研究。
主要发现
- 特立帕肽在29项研究中 examined,1年持续性率10-87%(中位数55%),2年10-69%(中位数29.5%),1年依从率21-89%(中位数53%),2年37-68%(中位数40%)。
- 唑来膦酸在10项研究中报告第二剂持续性率34-73%(中位数42%),第三剂20-54%(中位数35.8%)。
- 伊班膦酸在10项研究中报告1年持续性率31-58%(中位数47.5%),2年13-35%(中位数25%),依从率分别为21-72%(中位数47.3%)和15-58%(中位数36.5%)。
- 地舒单抗在19项研究中报告第二剂(1年)持续性率61-100%(中位数81%),第四剂(2年)36-99%(中位数45.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 各研究报告的持续性和依从率存在显著异质性。
- 多数已发表数据来自短期研究,需要评估肠外骨质疏松疗法的长期依从性与持续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is a chronic disease of low bone mass and fragility. Treatment is frequently compromised by suboptimal medication compliance causing increased morbidity. This review investigates adherence and persistence to parenteral osteoporosis therapies. Findings reveal parenteral medications requiring reduced dosing frequency have higher compliance than oral therapies. This systematic review examines real-world adherence to parenteral osteoporosis therapies. We searched PubMed, Medline, and EMBASE databases for English language observational studies that examined patient adherence and/or persistence to parenteral osteoporosis treatments (teriparatide sc, ibandronate iv, zoledronic acid iv, and denosumab sc) in adults with osteoporosis published up to September 2018. Studies with only self-reported adherence or persistence data and those with less than 20 patients were excluded. Quality assessment of included studies was completed using the Newcastle-Ottawa quality assessment scale (NOS). We identified 40 eligible studies. Teriparatide was examined in 29 studies, with persistence rates of 10-87% (median 55%) at 1 year and 10-69% (median 29.5%) at 2 years, and adherence rates of 21-89% (median 53%) at 1 year and 37-68% (median 40%) at 2 years. Ten studies of zoledronic acid reported persistence rates of 34-73% (median 42%) for second dose and 20-54% (median 35.8%) for third dose. Ten studies of ibandronate adherence reported and 2-year persistence rates of 31-58% (median 47.5%) in 1 year and 13-35% (median 25%) at 2 years, and adherence rates of 21-72% (median 47.3%) and 15-58% (median 36.5%) respectively. Denosumab was reported in 19 studies, with second (1 year) and fourth (2 year) dose persistence rates of 61-100% (median 81%) and 36-99% (median 45.5%). There is substantial heterogeneity in reports of persistence and adherence rates with parenteral osteoporosis therapies. Most of the published data are from short-term studies and evaluations of long-term adherence and persistence with parenteral therapies for osteoporosis are needed.
引用
- Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020. PMID: 32613409. doi:10.1007/s00198-020-05507-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。